SGMO logo

SGMOSangamo Therapeutics Inc

$0.2228
$0.0051
(2.34%)
Today
Updated: 12:14 PM EDT
Reported EarningsMay 14
Mkt Cap$90.19M
Vol1.21M
News
all
press releases
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates
Sangamo (SGMO) delivered earnings and revenue surprises of -100.00% and -84.82%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
More News
News Placeholder
Sangamo Therapeutics (SGMO) to Release Earnings on Monday
Sangamo Therapeutics (NASDAQ:SGMO) will be releasing its Q1 2026 earnings after the market closes on Monday, May 11. (View Earnings Report at...
MarketBeat
News Placeholder
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Short Interest Update
Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) was the target of a significant increase in short interest in April. As of April 15th, there was short interest totaling 42,883,635 shares, an increase of 14.0% from the March 31st total of 37,605,702 shares. Based on an average daily...
MarketBeat
News Placeholder
Sangamo Therapeutics (NASDAQ:SGMO) Insider Sells $17,456.75 in Stock
Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) insider Gregory Davis sold 69,827 shares of the stock in a transaction on Wednesday, April 22nd. The shares were sold at an average price of...
MarketBeat
News Placeholder
Sangamo Therapeutics (NASDAQ:SGMO) SVP Sells $89,944.92 in Stock
Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) SVP Nathalie Dubois-Stringfellow sold 345,942 shares of Sangamo Therapeutics stock in a transaction on Tuesday, April 21st. The stock was...
MarketBeat
News Placeholder
Gregory Davis Sells 69,827 Shares of Sangamo Therapeutics (NASDAQ:SGMO) Stock
Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) insider Gregory Davis sold 69,827 shares of the firm's stock in a transaction dated Wednesday, April 22nd. The shares were sold at an...
MarketBeat
News Placeholder
Sangamo Therapeutics (NASDAQ:SGMO) Lowered to Strong Sell Rating by Zacks Research
Zacks Research lowered shares of Sangamo Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Thursday...
MarketBeat
News Placeholder
HC Wainwright Has Negative Forecast for SGMO FY2026 Earnings
Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - Stock analysts at HC Wainwright dropped their FY2026 earnings per share estimates for shares of Sangamo Therapeutics in a research note issued...
MarketBeat
News Placeholder
Equities Analysts Issue Forecasts for SGMO FY2028 Earnings
Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - HC Wainwright reduced their FY2028 earnings per share estimates for shares of Sangamo Therapeutics in a report released on Thursday, April...
MarketBeat
News Placeholder
Why PEPG, SGMO, PHR Are Among Top Premarket Losers Today
However, retail sentiment on Stocktwits across all three firms was ‘extremely bullish’ amid ‘extremely high’ message volumes.
Stocktwits
<
1
2
...
>